Healthcare Industry News: Zimmer
News Release - October 4, 2006
Journal of the American Medical Directors Association Publishes Positive Independent National Study of Nymox's AlzheimAlert(TM) Urine Test For Alzheimer's DiseaseHASBROUCK HEIGHTS, N.J.--(HSMN NewsFeed)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX ) is pleased to announce the publication of a peer-reviewed report on the successful results of a multi-center double blind independent clinical study of the Company's urinary AlzheimAlert(TM) test in the Journal of the American Medical Directors Association (www.jamda.com). The newly published independent peer-review study from 8 prestigious centers across the U.S. found the level of accuracy of the Alzheimalert(TM) urine test to be over 90%. The study was double-blind and involved expert assessments and state of the art clinical correlations and continued evaluations.
The article, "A Multi-Center Blinded Prospective Study of Urine Neural Thread Protein Measurements in Patients With Suspected Alzheimer's Disease," was authored by Dr. Ira Goodman of Orlando Regional Healthcare System, Dr. Greg Golden of Thomas Jefferson University Medical School, Dr. Stephen Flitman of 21st Century Neurology, Phoenix AZ, Dr. Kevin Xie of Centra Care Clinic, St. Cloud MN, Dr. Zinaida Lebedeva of University Hospitals Health Care System, Beachwood OH, Dr. Alireza Minagar of Louisiana State University Health Sciences Center, Shreveport LA, Dr. Earl Zimmerman of Albany Medical College, Albany NY, Dr. Ralph Richter of University of Oklahoma, Tulsa OK, and Dr. Susanna Levy, Matthew McConville and Dr. Paul Averback of Nymox Corp.
The AlzheimAlert(TM) test is Nymox's proprietary urine based diagnostic aid for Alzheimer's disease. It is the only proven accurate non-invasive AD test technology available. The test has the CE Mark, allowing it to be marketed in Europe, and is also available to physicians in the U.S. through the Company's national CLIA-certified Clinical Reference Laboratory in New Jersey at a cost of $295. Nymox currently has numerous initiatives underway for the AlzheimAlert(TM) testing technology, including marketing and distribution overseas, and global product development.
There are an estimated 4.5 million people with Alzheimer's disease in the United States alone; by 2050 this number is projected to increase almost three times to 13.2 million. Worldwide estimates of the current number of people with Alzheimer's disease range from 15 to 20 million. The annual national direct and indirect costs of caring for Alzheimer patients in the U.S. alone are estimated at $100 billion. The human toll on patients, families and caregivers is incalculable.
More information about Nymox is available at www.nymox.com, email: email@example.com, or 800-936-9669.
This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
Source: Nymox Pharmaceutical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.